refractory angina patients
regenerative therapy
clinical study
cost-efficient therapy
medical therapy
gene therapy
benefits of therapy
CCS angina score
placebo-controlled study Chronic angina pectoris
clinical validation
Clinical development
double-blinded Phase
cost-effective treatment of refractory anginaA phase
proof of principle testing of new regenerative VEGF-D therapy
European clinical centres
new cases
regenerative changes
placebo arms
individual
proposed trial
related quality of life
low levels of health
proof of concept
AdenoVEGF-D
substantial burden
health service
CCS class
ReGenHeart project
debilitating chronic disease
so-called MACE endpoints
MRI imaging endpoints
advanced PET
multiple hospitalizations
optimized catheter-mediated intramyocardial approach
annual mortality
final regulatory approval
extensive preclinical work
affected area
subject
therapeutic angiogenesis
safety
year
feasibility
dose
subgroup
patient's heart
healthcare system
potential
single procedure
angioplasty
surgery
primary endpoint
minutes
man
consortium
months